Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

NRX Pharmaceuticals (NRXP) EBITDA (2024 - 2025)

NRX Pharmaceuticals (NRXP) has disclosed EBITDA for 2 consecutive years, with -$8.6 million as the latest value for Q4 2025.

  • Quarterly EBITDA rose 5.08% to -$8.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$22.1 million through Dec 2025, up 10.23% year-over-year, with the annual reading at -$16.2 million for FY2025, 35.47% up from the prior year.
  • EBITDA for Q4 2025 was -$8.6 million at NRX Pharmaceuticals, down from -$5.9 million in the prior quarter.
  • The five-year high for EBITDA was -$1.6 million in Q3 2024, with the low at -$9.1 million in Q4 2024.